India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

The Centers for Disease Control and Prevention reported this week that the bacteria Shigella sonnei has become resistant to ciprofloxacin, the antibiotic that used to shorten the illness it caused ...

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in ...

Bharat Biotech has partnered with GSK to develop a Shigellosis vaccine. The altSonflex1-2-3 candidate is one of the most ...

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine ...

Five percent of Shigella infections are now resistant to standard antibiotics. This could be a predictor of what’s to come with other bacteria. By Dana G. Smith Multiple strains of the diarrhea ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...